Can we prescribe TMP/SMX prophylaxis without any concerns equally for all patients with rheumatic disease?

We read with great interest the recent article by Park  et al 1 and appreciate the authors’ efforts to assess the benefit and safety of trimethoprim-sulfamethoxazole (TMP/SMX) as primary prophylaxis for pneumocystis pneumonia in patients with rheumatic diseases, exposed to prolonged high-dose glucocorticoids. However, we would like to point out one concern in the incidence of …